Visit Health, a prominent healthtech platform, has successfully secured over ₹250 crore through a combination of primary capital infusion and secondary share purchases. The funds were raised from Docprime Technologies, a subsidiary of PB Fintech, along with contributions from other promoters and employees.
This significant capital injection will drive Visit Health’s growth strategy focusing on three key areas: expanding its team, broadening its network, and advancing its technology. The company plans to enhance its network by incorporating more doctors and clinics in Tier-II, III, and IV cities, and to improve its technological infrastructure for a seamless, cashless healthcare experience.
Vaibhav Singh, Co-Founder & MD of Visit Health, emphasized the importance of these investments in revolutionizing primary healthcare in India. “We are aiming to enhance our capabilities in people, network, and technology. Expanding our network and improving our technology are critical for delivering quality primary healthcare,” Singh said in an interview with CNBC-TV18.
Since its inception in 2016, Visit Health has partnered with over 400 corporates and 6,000 SMEs, collaborating with 18 insurers across various sectors. The platform currently serves close to 90 lakh individuals and aims to reach a crore mark soon.
Visit Health has demonstrated consistent profitability over the past four years, with revenues doubling annually. Last year, the company reported revenues of ₹130 crore and anticipates reaching ₹260 crore this year.
